Literature DB >> 18485514

Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up.

Shi-Jun Liu1, Zhi-Rong Guo, Xiao-Shu Hu, Ming Wu, Feng-Mei Chen, Guo-Dong Kang, Hui Zhou, Lu Guo.   

Abstract

AIMS: The aim of this study was to determine whether the metabolic syndrome (MS) preceded incidence of type-2 diabetes (T2DM) by 5 years and to investigate the interaction between impaired fasting glucose (IFG) and other components of MS.
METHODS: Subjects were recruited from the cohort study on the prevention of multiple metabolic disorders and MS in Jiangsu province, China; at the 5 years follow-up period (N=1844). The National Cholesterol Education Program Adult Treatment Panel III Asian criterion was used to define MS. In present study, we compared the T2DM risk among individuals with or without MS at baseline. Also the interaction between the IFG and other components of MS were evaluated.
RESULTS: Subjects with MS had a 2.3 (1.5-3.6) adjusted relative risk (aRR) of developing T2DM when compared with individuals without non-MS at baseline. Incidentally, the aRRs of MS components were 5.4 (2.6-10.8) for IFG, 2.6 (1.2-5.9) for greater waist circumference, 3.5 (1.6-7.4) for elevated triglyceride, 4.7 (2.3-9.9) for elevated blood pressure, and 2.4 (1.1-5.3) for low high density lipoprotein. After further adjustment of the components of MS, only IFG was found to be statistically significant. The T2DM risk of individuals combined with IFG increased by the number of other MS components. The result of interaction analysis was SI=1.41 but without significance.
CONCLUSIONS: Subjects with MS were at a higher risk of developing T2DM than those who did not have the syndrome. Also IFG was found to be an excellent predictor of T2DM. However, there was not a significant interaction between IFG and the other MS components.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18485514     DOI: 10.1016/j.diabres.2008.03.008

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  10 in total

1.  Evaluation of metabolic syndrome in patients with chronic low back pain.

Authors:  Mehmet Tuncay Duruöz; Yasemin Turan; Alev Gürgan; Hülya Deveci
Journal:  Rheumatol Int       Date:  2010-12-05       Impact factor: 2.631

2.  Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

Authors:  Francisco J Martinez-Martin; Alicia Macias-Batista; Cristina Comi-Diaz; Herminia Rodriguez-Rosas; Paula Soriano-Perera; Pablo Pedrianes-Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  The effect of diet counseling and physical activity on the components of metabolic syndrome in children: A Randomized Clinical Trial.

Authors:  Ashrafalsadat Hakim; Roya Bagheri; Kambiz Ahmadi Angali
Journal:  SAGE Open Med       Date:  2022-05-23

4.  Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.

Authors:  F J Martinez-Martin; H Rodriguez-Rosas; I Peiro-Martinez; P Soriano-Perera; P Pedrianes-Martin; C Comi-Diaz
Journal:  J Hum Hypertens       Date:  2010-11-25       Impact factor: 3.012

5.  Evaluation of metabolic syndrome in patients with chronic low back pain: using the fourth Korea national health and nutrition examination survey data.

Authors:  Jae Yong Ha
Journal:  Chonnam Med J       Date:  2011-12-26

6.  Predictive Power for Type 2 Diabetes Mellitus using Dynamic Change of Metabolic Syndrome, Dynamic Change of Fasting Plasma Glucose, Metabolic Syndrome and Fasting Plasma Glucose.

Authors:  Hui Zhou; Chen Yang; Chen Dong; Zhirong Guo; Xiaoshu Hu; Yong Xu; Zhengyuan Zhou
Journal:  Iran J Public Health       Date:  2014-04       Impact factor: 1.429

7.  Dysglycaemia and Other Predictors for Progression or Regression from Impaired Fasting Glucose to Diabetes or Normoglycaemia.

Authors:  L de Abreu; Kara L Holloway; Mark A Kotowicz; Julie A Pasco
Journal:  J Diabetes Res       Date:  2015-07-27       Impact factor: 4.011

8.  Hypertriglyceridemic Waist Phenotype and Lipid Accumulation Product: Two Comprehensive Obese Indicators of Waist Circumference and Triglyceride to Predict Type 2 Diabetes Mellitus in Chinese Population.

Authors:  Minrui Xu; Mingtao Huang; Deren Qiang; Jianxin Gu; Yong Li; Yingzi Pan; Xingjuan Yao; Wenchao Xu; Yuan Tao; Yihong Zhou; Hongxia Ma
Journal:  J Diabetes Res       Date:  2020-12-02       Impact factor: 4.011

9.  An exploratory analysis of dynamic change of metabolic syndrome in relation to the risk of developing cardiovascular disease in a chinese cohort.

Authors:  H Zhou; Zr Guo; Xs Hu; Lg Yu; Bh Xu; M Wu; Zy Zhou; C Yang
Journal:  Iran J Public Health       Date:  2012-04-30       Impact factor: 1.429

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.